FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that LockeT sales for Q2 2025 are on track to be the highest to date. Second quarter 2025 LockeT sales are already outpacing Q2 2024 sales with a 200% increase. Catheter Precision now has several US hospitals that are on track to issue more than $100,000 in purchase ord ...

NEW YORK, June 12, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of West Pharmaceutical Services, Inc. (NYSE: WST).Shareholders who purchased shares of WST during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/west-pharmaceutical-services-inc-loss-submission-form/?id=152569&from=4CLA ...

Nano-X Imaging (NNOX) Conference June 11, 2025 01:45 PM ET Speaker0 Welcome to submit questions using the Zoom Q and A interface at the bottom of your screen. After the presentation, we'll open to your questions. And with that, Ron, I'll turn it over to you. Speaker1 You, Alex, and good afternoon for everyone. Before we'll get started, I would like to remind everyone that I'll be making statements during this presentation that may be deemed forward looking statements regarding our activities, commercializat ...

Key Takeaways ISRG posted first-quarter revenue of $2.25B driven by da Vinci and Ion procedure growth. ISRG cut gross margin forecast to 65-66.5% due to tariff-driven cost increases on imported components. ISRG's $9B cash reserve and strong recurring revenue support long-term innovation plans.Intuitive Surgical (ISRG) delivered strong top-line growth in the first quarter of 2025, with revenue rising 19% year over year to $2.25 billion, supported by a 17% increase in da Vinci procedures and a 58% increase ...

NEW YORK, June 11, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Treace Medical Concepts, Inc. (NASDAQ: TMCI) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Treace Medical caused the company to misrepresent or fail to disclose (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System; (2) as a result, T ...

Core Viewpoint - The Schall Law Firm is investigating Bausch + Lomb Corporation for potential violations of securities laws, focusing on misleading statements and undisclosed information that may have affected investors [1][2]. Financial Performance - Bausch + Lomb reported an adjusted net loss of $54 million for Q1 2025, a significant decline compared to a net income of $24 million in the same period of the previous year [2]. - The company has lowered its full-year growth outlook, attributing part of this change to the recall of its enVista product [2].

Core Insights - Inspira Technologies has begun to see positive impacts from the adoption of its FDA-cleared ART100 system, marking a significant milestone in its commercialization efforts [1][4] - The ART100 system has been successfully integrated into clinical workflows at leading tier-one U.S. hospitals, indicating growing confidence in its capabilities [2][4] - There is increasing interest from additional U.S. and international healthcare institutions and governmental authorities regarding the ART100, prompting the company to scale up operational capabilities [3][4] Company Overview - Inspira Technologies specializes in advanced respiratory support and real-time blood monitoring solutions, with the ART100 system approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. [5] - The company is also developing the INSPIRA ART500, a next-generation system designed for oxygenation while patients remain awake and breathing spontaneously [5] - Inspira is advancing its proprietary blood sensor platform, HYLA™, which offers continuous, non-invasive monitoring, positioning the company as an attractive player in the life-support and MedTech landscape [5]

Core Viewpoint - Shineco, Inc. announces a stock purchase program led by CEO Jennifer Zhan and CFO Sam Wang, intending to buy up to $2,000,000 of the company's common stock, reflecting their belief that the stock is undervalued [1][3]. Company Overview - Shineco, Inc. focuses on providing innovative diagnostic medical products and related medical devices, aiming to improve quality of life through safe and efficient health products [3]. - The company has developed 33 types of in vitro diagnostic reagents and related medical devices, in addition to producing and selling healthy and nutritious foods [3]. Stock Purchase Program Details - The stock purchase program will involve open market purchases funded by the personal cash of Ms. Zhan and Mr. Wang, with a maximum purchase price of $1.50 per share [1][2]. - The timing and number of shares purchased will depend on various factors, including the company's business conditions and stock pricing [2]. Management's Perspective - CEO Jennifer Zhan emphasizes that the insider-led purchase initiative reflects management's confidence in Shineco's long-term growth potential and the belief that the current stock price does not accurately reflect the company's technological advantages and market potential [3].

WHITE BEAR LAKE, Minn., June 11, 2025 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announced that Brent Lucas, CEO of Envoy Medical, will present live at the Life Sciences Virtual Investor Frum hosted by VirtualInvestorConferences.com, on June 12th, 2025. DATE: June 12th TIME: 3pm Eastern LINK: REGISTER HERE Available for 1x1 meetings: June 12th throu ...

-Aetna authorizes claim for PoNS Device at out-of-network negotiated price of $18,350, becoming the third payer to join Anthem and United in providing PoNS reimbursement- -Out of Network reimbursement is only the first step towards expanding third-party paid access to PoNS- NEWTOWN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait def ...